Lung Cancer Nucleic Acid Test Clinicals Under Development By DiagnoCure
This article was originally published in The Gray Sheet
Executive Summary
DiagnoCure says its R&D collaboration with Compugen Ltd. will spur the launch of pivotal clinical studies evaluating a nucleic acid-based test for lung cancer by mid-2003
You may also be interested in...
Abbott Lands FISH Technology For Cancer DNA Probe Tests With Vysis Buy
Abbott Laboratories is expanding its molecular diagnostics offerings to include tests for cancer and other genetic diseases through the $355 mil. cash acquisition of Vysis under a definitive agreement, announced Oct. 24.
Centocor Exiting Diagnostics Business To Focus Exclusively on Therapeutics
Centocor's commitment to its core pharmaceutical operation has been reinforced by the company's Oct. 30 announcement that it will sell its oncology diagnostics business to the Japanese firm Fujirebio for $37.5 mil.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.